Full Breakdown
CRISPR Therapeutics Among the Most Shorted Mid-Cap Biotech Stocks: Risks, Upside, and Market Context
6/6/2026, 8:13:56 AM
CRISPR Therapeutics: A Heavily Shorted Biotech with Upside Potential
CRISPR Therapeutics AG (NASDAQ: CRSP) appears at No. 7 on a list of the ten most shorted mid-cap and small-cap stocks identified for June 2026. The company carries a short float of 30.48 percent, a market capitalization of roughly $5.23 billion, and an estimated upside potential of 38.03 percent. Its portfolio centers on in-vivo CRISPR/Cas9 gene-editing programs delivered via a proprietary liver-directed lipid nanoparticle platform. Current pipeline highlights include CTX310 for severe hypertriglyceridemia, CTX460 for alpha-1 antitrypsin deficiency, and CTX340 targeting angiotensinogen in refractory hypertension.
Market Rotation and Short Interest: Setting the Stage
During the first half of 2026, investor capital shifted from mega-cap technology firms toward smaller companies, lifting the Russell 2000 index about 18 percent—nearly double the S&P 500’s 9 percent gain. This rotation increased attention on stocks with high short interest, defined as investors borrowing shares to sell them in anticipation of a price decline. When positive news forces short sellers to cover, the resulting buying pressure can trigger a short-squeeze rally. The current environment of improved risk appetite has amplified searches for “most shorted stocks to buy” and “short-squeeze candidates.”
Key Players and Stakeholders
- CRISPR Therapeutics AG – the biotech firm at the center of the analysis.
- Citizens Research – reiterated a Market Perform rating and set a price target of $60 on May 27, 2026.
- Wells Fargo Investment Institute – analyst Alex Sagal warned that the broader small-cap rally may conceal underlying weakness in profitability and balance-sheet strength.
- Institutional investors – 32 hedge funds hold positions in CRSP, indicating professional interest despite the high short float.
Data Snapshot
| Metric | Value |
|---|---|
| Short float | 30.48 % |
| Market cap | $5.23 billion |
| Upside potential (estimated) | 38.03 % |
| Hedge-fund holders | 32 |
| Recent analyst price target | $60 |
| Short-interest screening threshold (list) | >= 20 % short float, market cap $300 million–$10 billion, >= 20 % upside potential |
Official Analyst Views
Citizens Research reaffirmed a Market Perform rating for CRISPR Therapeutics and projected a target price of $60, citing a positive outlook for in-vivo editing of cardiovascular disease. Conversely, Wells Fargo Investment Institute analyst Alex Sagal cautioned that the small-cap rally may mask weaker earnings, higher debt levels, and tighter balance sheets, especially for companies with elevated short interest.
Critics’ Viewpoint
Bearish arguments highlighted in the broader discussion of shorted stocks include concerns over limited profitability, elevated debt, narrow customer bases, and sensitivity to interest-rate changes. The high short float itself is presented as a signal that market participants perceive material risk in the company’s current fundamentals or growth trajectory.
Why It Matters for Investors and Gene-Editing
If CRISPR’s in-vivo programs achieve sustained lipid-lowering or hypertension control, the therapeutic impact could be significant for cardiovascular disease management. Successful trials would not only validate the company’s scientific platform but also potentially catalyze a re-rating by analysts and a rapid price appreciation, given the existing short-interest pressure.
Unresolved Issues
Sources do not provide a consensus on whether CRISPR’s fundamentals justify the projected upside. The tension between bullish expectations of pipeline progress and bearish concerns about financial health remains unresolved, creating a gap for investors to evaluate.
What’s Next
Upcoming milestones include Phase 1b readouts for CTX310 and continued data releases from the European Atherosclerosis Society Congress. Market participants will watch for any catalyst that could trigger short-seller covering or, alternatively, reinforce the bearish narrative. The interplay of clinical outcomes and short-interest dynamics will shape CRISPR Therapeutics’ trajectory in the latter half of 2026.
